CHEK2 and central nervous system cancer: Mechanistically, loss of Chek2 enhances antigen presentation, STING pathway activation, and PD-L1 expression in mouse gliomas, supporting Chek2 as a promising target for enhancement of response to immune checkpoint blockade therapy in glioblastoma (GBM) (Dmello et al., 2023).